Bicyclo Ring System Having The Additional Hetero Ring As One Of The Cyclos Patents (Class 514/233.5)
  • Patent number: 6835731
    Abstract: Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: December 28, 2004
    Assignee: AnorMED, Inc.
    Inventors: Gary Bridger, Renato Skerlj, Al Kaller, Curtis Harwig, David Bogucki, Trevor R. Wilson, Jason Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis, Rosaria Maria Di Fluri
  • Publication number: 20040248889
    Abstract: Substituted 5,6,6a, 11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds, and processes for the production thereof, pharmaceutical compositions containing these compounds and the use thereof in treatment methods and for the production of pharmaceutical preparations for specific indications, in particular for the treatment of pain.
    Type: Application
    Filed: February 3, 2004
    Publication date: December 9, 2004
    Applicant: Gruenenthal GmbH
    Inventors: Matthias Gerlach, Michael Przewosny, Werner Guenter Englberger, Elke Reissmueller, Petra Bloms-Funke, Corinna Maul, Utz-Peter Jagusch
  • Patent number: 6828134
    Abstract: The present invention relates to a process for preparing 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen-2-ol compounds useful as an estrogen agonist.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: December 7, 2004
    Assignee: Pfizer Inc.
    Inventor: Kevin K. Liu
  • Patent number: 6828320
    Abstract: Substituted heteroaromatic compounds, and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: December 7, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith
  • Publication number: 20040242559
    Abstract: The invention relates to compounds of formula (I): 1
    Type: Application
    Filed: April 23, 2004
    Publication date: December 2, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Antonio Ugolini, Herve Bouchard
  • Patent number: 6797708
    Abstract: This invention provides substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: September 28, 2004
    Assignee: Wyeth
    Inventors: John C. McKew, Steven Y. Tam, Katherine L. Lee, Lihren Chen, Paresh Thakker, Fuk-Wah Sum, Mark Behnke, Baihua Hu, James D. Clark
  • Patent number: 6780859
    Abstract: This invention relates to novel benzofuran and dihydrobenzofuran compounds, pharmaceutical compositions containing such compounds, and methods of treating beta-3 adrenoreceptor-mediated conditions with such compositions.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: August 24, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan H. Ladouceur, William R. Schoen, Michael J. Burke
  • Publication number: 20040097564
    Abstract: Provided, among things, is a method of decreasing intraocular pressure in an animal, including a human, comprising administering an intraocular pressure decreasing amount of a compound of the formula I: 1
    Type: Application
    Filed: September 25, 2003
    Publication date: May 20, 2004
    Inventor: Martin Gall
  • Patent number: 6737042
    Abstract: The present invention relates to the delivery of drug esters through an inhalation route. Specifically, it relates to aerosols containing drug esters that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of drug ester. In a method aspect of the present invention, a drug ester is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of drug ester, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: May 18, 2004
    Assignee: Alexza Molecular Delivery Corporation
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Publication number: 20040087584
    Abstract: PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs.
    Type: Application
    Filed: July 18, 2003
    Publication date: May 6, 2004
    Applicant: MEMORY PHARMACEUTICALS CORP.
    Inventors: Richard A. Schumacher, Allen T. Hopper, Ashok Tehim
  • Patent number: 6730670
    Abstract: A compound of the formula Compounds of formula I have a good affinity to the A2A receptor and are useful for the treatment of diseases mediated by this receptor.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: May 4, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Alanine, Alexander Flohr
  • Patent number: 6730671
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes, for making such novel compounds.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: May 4, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Patent number: 6723718
    Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: April 20, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Patent number: 6720320
    Abstract: The present invention relates to a phenoxypropylamine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof or a pharmaceutically acceptable salt thereof and hydrates thereof, which simultaneously show selective affinity for and antagonistic activity against 5-HT1A receptor, as well as 5-HT reuptake inhibitory activity, and can be used as antidepressants quick in expressing an anti-depressive effect.
    Type: Grant
    Filed: November 23, 2001
    Date of Patent: April 13, 2004
    Assignee: Mitsubishi Pharma Corporation
    Inventors: Akira Nishiyama, Masahiro Bougauchi, Takanobu Kuroita, Masanori Minoguchi, Yasunori Morio, Kouji Kanzaki
  • Patent number: 6716840
    Abstract: Compounds having the general structure I are provided: X and Y are independently selected from the group consisting of CH2, N, NR9, C═O, C═S, S═O, SO2, S, O, (CR6R7)n, C(═O)—(CR6R7)n, and C(═S)—(CR6R7)n, where n is 1, 2, or 3. W is selected from the group consisting of and L is selected from the group consisting of N, O, S, S═O, SO2, C(O), NC(O), NC(S), OC(O), OC(S), C(NR10), C(NOR10), and a covalent bond. Z1, Z2, and Z3 are independently selected from the group consisting of substituted carbon and nitrogen. Compounds of formula I are agonists of the melanocortin-4 receptor (“MC-4r”) and therefore may have useful properties for controlling diseases related to MC-4r action in humans, such as obesity and type II diabetes.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: April 6, 2004
    Assignee: Chiron Corporation
    Inventors: Daniel Chu, Rustum S. Boyce, David Duhl, Bryan H. Chang
  • Patent number: 6699860
    Abstract: This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: March 2, 2004
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan H. Ladouceur, William H. Bullock, Steven R. Magnuson, Stephen J. O'Connor, Roger A. Smith, Quanrong Shen, Qingjie Liu, Ning Su, Emil J. Velthuisen, Ann-Marie Campbell, Paul P. Ehrlich
  • Patent number: 6693116
    Abstract: The present application relates to compounds of the formula wherein R1 is hydrogen, halogen or lower alkoxy; R2 is hydrogen or is —C(O)-lower alkyl or —C(O)-phenyl, wherein the phenyl ring is unsubstituted or substituted by one or two substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy and trifluoromethyl, or is —C(O)-furanyl or —C(O)-thiophenyl, wherein the rings are unsubstituted or substituted by halogen; or a pharmaceutically acceptable salt thereof. The compounds are useful in the treatment of diseases associated with the adenosine A2 receptor.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: February 17, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Matthias Heinrich Nettekoven, Sebastien Schmitt
  • Publication number: 20040029858
    Abstract: 2-(III-Indol-3-yl)-2-oxo-acetamide derivatives of formula (I) having antitumor activity in particular against solid tumors, specifically colon and lung tumors.
    Type: Application
    Filed: July 10, 2003
    Publication date: February 12, 2004
    Inventors: Ernesto Menta, Nicoletta Pescalli
  • Patent number: 6689790
    Abstract: A compound of formula wherein R1 is —NR′R″, wherein R′ and R″ are independently selected from the group consisting of lower alkyl, —(CH2)n—C(O)NRaRb, —(CH2)n,-heteroaryl, —(CH2)n-aryl, —(CH2)n—CN, —(CH2)n—O-lower alkyl or —(CH2)n-cycloalkyl, or R′ and R″ form together with the N-atom a five or six-membered non-aromatic ring, containing no or one additional heteroatom selected from the group consiting of O and S, and said ring being unsubstituted or substituted by one or two substituents, selected from the group consisting of lower alkyl, —C(O)NRaRb and —(CH2)n—O-lower alkyl, and RaRb are independently from each other hydrogen or lower alkyl; R2 is aryl or heteroaryl, unsubstituted or substituted by lower alkyl or halogen; and n is 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: February 10, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Matthias Heinrich Nettekoven, Sebastien Schmitt
  • Patent number: 6683079
    Abstract: 3-(amino- or aminoalkyl) pyridinone derivatives having the formula (1) wherein Q, X, Y, and R3-R6 are as defined, which derivatives are useful for the treatment of HIV related diseases.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: January 27, 2004
    Assignees: Centre National de la Recherche Scientifique, Insitut Curie
    Inventors: Emile Bisagni, Valerie Dolle, Chi Hung Nguyen, Claude Monneret, David Grierson, Anne-Marie Aubertin
  • Publication number: 20040006069
    Abstract: 1
    Type: Application
    Filed: March 27, 2003
    Publication date: January 8, 2004
    Inventors: Kyungae Lee, Scott Mitchell, Robert Ohliger, Lu Yan Zhang, He Zhao, Kevin Currie
  • Publication number: 20040002495
    Abstract: A compound of formula I 1
    Type: Application
    Filed: May 19, 2003
    Publication date: January 1, 2004
    Inventors: Philip Sher, Gang Wu, Terry Stouch, Bruce Ellsworth
  • Publication number: 20030236281
    Abstract: NK3 receptor antagonists of formula (I): 1
    Type: Application
    Filed: May 29, 2001
    Publication date: December 25, 2003
    Inventors: Carlo Farina, Giuseppe Arnaldo Maria Giardina, Mario Grugni, Luca Francesco Raveglia
  • Publication number: 20030232804
    Abstract: The present application describes glycinamidic compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
    Type: Application
    Filed: November 25, 2002
    Publication date: December 18, 2003
    Inventors: Donald J.P. Pinto, Wei Han, Zilun Hu, Jennifer Qiao
  • Publication number: 20030232816
    Abstract: A compound of the formula I: 1
    Type: Application
    Filed: September 10, 2002
    Publication date: December 18, 2003
    Applicant: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Pierre Louis Beaulieu, Gulrez Fazal, James Gillard, George Kukolj, Volkhard Austel
  • Publication number: 20030232828
    Abstract: The present invention provides compounds of formula I and the use thereof for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: June 3, 2003
    Publication date: December 18, 2003
    Applicant: Wyeth
    Inventors: Ronald Charles Bernotas, Steven Edward Lenicek, Schuyler A. Antane, Ping Zhou, Yanfang Li
  • Publication number: 20030229090
    Abstract: Disclosed are compounds of formula (I): 1
    Type: Application
    Filed: April 15, 2003
    Publication date: December 11, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Scott E. Jakes, Joachim Heider, Mark A. Bobko, Renee L. Des Jarlais, Mark Player, James Rinker, Michael Winters, Bao-Ping Zhao
  • Publication number: 20030225053
    Abstract: Disclosed are amide compounds of formula(I): 1
    Type: Application
    Filed: April 10, 2003
    Publication date: December 4, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Donghong Amy Gao, Daniel R. Goldberg, Abdelhakim Hammach, Ming-Hong Hao, Victor Marc Kamhi, Neil Moss, Kevin Chungeng Qian, Gregory Paul Roth, Christopher Ronald Sarko, Alan David Swinamer, Zhaoming Xiong
  • Publication number: 20030225078
    Abstract: A compound of formula I, 1
    Type: Application
    Filed: April 16, 2003
    Publication date: December 4, 2003
    Applicants: Orion Corporation, Oy Juvantia Pharma Ltd.
    Inventors: Siegfried Wurster, Mia Engstrom, Juha-Matti Savola, Iisa Hoglund, Jukka Sallinen, Antti Haapalinna, Andrei Yurievitch Tauber, Anna-Marja Katariina Hoffren, Harri Elias Salo
  • Patent number: 6656946
    Abstract: Compounds of the formula having an inhibitory effect on signal transduction mediated by tyrosine kinases and their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: December 2, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Birgit Jung, Stefan Blech, Flavio Solca
  • Publication number: 20030220377
    Abstract: This invention relates to compounds, in particular indoles, that are useful as estrogen agonists and antagonists and pharmaceutical uses thereof. The present invention also relates to indoles that are selective for the ER&bgr; receptor and pharmaceutical uses thereof. The compounds have utility in that they may be used to treat estrogen mediated disorders.
    Type: Application
    Filed: May 7, 2003
    Publication date: November 27, 2003
    Inventor: Richard Chesworth
  • Publication number: 20030220319
    Abstract: This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: 1
    Type: Application
    Filed: January 31, 2003
    Publication date: November 27, 2003
    Inventors: Robert Greenhouse, Saul Jaime-Figueroa, Lubica Raptova
  • Patent number: 6653305
    Abstract: A compound of formula (I) wherein: Ra is a benzyl or 1-phenylethyl group or a phenyl group substituted by the groups R1 and R2, wherein: R1 is a hydrogen, fluorine, chlorine, or bromine atom, or a methyl, trifluoromethyl, cyano, or ethynyl group, and R2 is a hydrogen or fluorine atom; Rb is an R3O—CO—CH2—N—CH2—CH2—OH group optionally substituted at the methylene groups by 1 or 2 methyl or ethyl groups, wherein R3 is a hydrogen atom or a C1-4-alkyl group, a 2-oxomorpholin-4-yl group optionally substituted by 1 or 2 methyl or ethyl groups, or a N-[(1,3-dioxolan-2-yl)methyl]methylamino group; Rc is a hydrogen atom, or a methoxy, ethoxy, 2-methoxyethoxy, 2-ethoxyethoxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy, tetrahydropyran-4-yloxy, tetrahydrofuranylmethoxy, or tetrahydropyranylmethoxy group; and n is 1, 2, or 3
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: November 25, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Birgit Jung, Stefan Blech, Flavio Solca
  • Publication number: 20030216390
    Abstract: Melanin concentrating hormone receptor ligands (especially substituted benzoimidazole analogues), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    Type: Application
    Filed: January 9, 2003
    Publication date: November 20, 2003
    Inventors: Robert W. DeSimone, John Peterson, Cheryl Steenstra, Yiping Shen, Linda Gustavson, Rajagopal Bakthavatchalam, Alan Hutchison
  • Publication number: 20030207877
    Abstract: The present invention provides a compound of formula I 1
    Type: Application
    Filed: December 19, 2002
    Publication date: November 6, 2003
    Inventors: Joseph Walter Strohbach, Steven P. Tanis, Malcolm Wilson Moon, James A. Nieman, Thomas J. Beauchamp, Jill M. Northuis, William D. McGhee
  • Publication number: 20030207887
    Abstract: This invention comprises the novel compounds of formula (I) 1
    Type: Application
    Filed: March 24, 2003
    Publication date: November 6, 2003
    Inventors: Patrick Rene Angibaud, Marc Gaston Venet, Laurence Anne Mevellec
  • Patent number: 6638972
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: October 3, 2002
    Date of Patent: October 28, 2003
    Assignee: Wyeth
    Inventors: Michael Gerard Kelly, Lynne Padilla Greenblatt, Gan Zhang, Yvette L. Palmer, Steven Edward Lenicek
  • Publication number: 20030199513
    Abstract: The invention relates to the use of cinnoline derivatives of formula (I) 1
    Type: Application
    Filed: December 5, 2002
    Publication date: October 23, 2003
    Applicant: ZENECA LIMITED
    Inventors: Andrew Peter Thomas, Laurent Francois Andre Hennequin
  • Publication number: 20030195204
    Abstract: The present invention relates to a novel use, in particular a novel pharmaceutical use for a series of quinoline derivatives.
    Type: Application
    Filed: May 7, 2002
    Publication date: October 16, 2003
    Applicant: SmithKline Beecham S.p.A.
    Inventors: Giuseppe Arnaldo Maria Giardina, Carlo Farina, Mario Grugni, Luca Francesco Raveglia
  • Publication number: 20030195208
    Abstract: This invention relates to phthalimido derivatives of the formula 1
    Type: Application
    Filed: March 13, 2003
    Publication date: October 16, 2003
    Inventors: Andrea Cesura, Rosa Maria Rodriguez Sarmiento, Andrew William Thomas, Rene Wyler
  • Publication number: 20030181447
    Abstract: This invention is directed to 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives useful as &dgr;-opioid or &mgr;-opioid receptor modulators. Depending on their agonist or antagonist effect, the compounds are useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.
    Type: Application
    Filed: February 7, 2003
    Publication date: September 25, 2003
    Inventors: Robert E. Boyd, John R. Carson, Steven J. Coats, Lou Anne Neilson, Philip M. Pitis, Wu-Nan Wu
  • Publication number: 20030176399
    Abstract: The present invention is directed to formulations comprising 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Methods of treating diseases related to abnormal PK activity utilizing the formulations comprising these compounds and methods of making these formulations are also disclosed.
    Type: Application
    Filed: November 21, 2002
    Publication date: September 18, 2003
    Applicant: SUGEN INCORPORATED
    Inventors: Ping Gao, Anand Sistla, Narmada Shenoy
  • Publication number: 20030176400
    Abstract: Indole derivatives represented by formula (I): 1
    Type: Application
    Filed: December 13, 2002
    Publication date: September 18, 2003
    Inventors: Kazuhiko Torisu, Kaoru Kobayashi, Fumio Nambu
  • Publication number: 20030176421
    Abstract: Stasis is treated or prevented in all or any part or parts of the stomach of a patient, especially a human patient, in need of such treatment, where said stasis results from hypomotility in the stomach, particularly gastric hypomotility with delayed emptying of the liquid and/or solid contents of the stomach. Gastric or gastrointestinal disorders are also treated which are characterized by one or more symptoms selected from pain, nausea, vomiting, heartburn, postprandial discomfort, indigestion and gastroesophageal reflux. Such treatment or prevention is achieved by administering to the patient a therapeutically effective amount of an inhibitor of phosphodiesterase-4 (PDE4), including isozyme subtypes thereof, sufficient to treat or prevent such hypomotility or gastric or gastrointestinal disorder in said patient.
    Type: Application
    Filed: December 30, 1999
    Publication date: September 18, 2003
    Inventors: JOHN W. WATSON, PAUL L. R. ANDREWS, ANTHONY J. WOODS
  • Publication number: 20030171354
    Abstract: The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds.
    Type: Application
    Filed: August 21, 2002
    Publication date: September 11, 2003
    Applicant: AstraZeneca AB
    Inventors: Michael Wardleworth, Alexander Graham Dossetter, Christopher Thomas Halsall
  • Publication number: 20030171373
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: January 29, 2003
    Publication date: September 11, 2003
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Michael Paal, Gerd Ruhter, Kenneth J. Ruterbories, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Publication number: 20030171372
    Abstract: The invention provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. In accordance with the invention, at least one cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus.
    Type: Application
    Filed: January 16, 2003
    Publication date: September 11, 2003
    Applicant: Immugen Pharmaceuticals, Inc.
    Inventor: Craig R. Travis
  • Publication number: 20030171353
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: December 19, 2002
    Publication date: September 11, 2003
    Applicant: Wyeth
    Inventors: Derek Cecil Cole, Joseph Raymond Stock, William Joseph Lennox, Ping Zhou
  • Publication number: 20030166615
    Abstract: The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.
    Type: Application
    Filed: October 19, 2002
    Publication date: September 4, 2003
    Inventors: David G. Hangauer, Moustafa E. El-Araby, Karen L. Milkiewicz
  • Patent number: 6610687
    Abstract: The invention relates to benzofuranylsulfonates of the general formula (I), their preparation and their use for the treatment of inflammation.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: August 26, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Gabriele Bräunlich, Mazen Es-Sayed, Rüdiger Fischer, Burkhard Fugmann, Rolf Henning, Stephan Schneider, Michael Sperzel, Karl-Heinz Schlemmer, Graham Sturton, Mary F. Fitzgerald, Barbara Briggs, Arnel Concepcion, William Bullock